Accelerate Diagnostics Reports First Quarter 2022 Financial Results
Accelerate Diagnostics (AXDX) reported a 20% increase in net sales for Q1 2022, totaling $3.0 million, driven by a 29% rise in recurring revenues. The company ended Q1 with 313 revenue-generating instruments and 76 contracted instruments in progress. However, gross margin decreased to 27% from 36% in Q1 2021 due to rising production costs. The firm's net loss was $14.2 million, translating to $0.21 per share. Despite a cash burn of $13.2 million in the quarter, they improved their balance sheet by raising $4 million from insider financing and reducing debt by $14 million.
- 20% increase in net sales to $3.0 million.
- 29% rise in recurring revenues.
- 313 revenue-generating instruments live in the U.S.
- Raised $4 million from an insider financing round.
- Reduced debt by $14 million.
- Gross margin decreased to 27% from 36% year-over-year.
- Net loss of $14.2 million and $0.21 per share.
TUCSON, Ariz., May 16, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2022.
"First quarter financial results were consistent with our expectations," commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc. "We also launched new products, progressed key R&D milestones, and improved our balance sheet position during the quarter."
First Quarter 2022 Highlights
- Added 2 contracted instruments and brought 5 instruments live in the U.S. in the quarter.
- Added numerous Arc evaluation contracts in the U.S.
- Ended the first quarter with 313 U.S. clinically live and revenue-generating instruments, with another 76 U.S. contracted instruments in the process of being implemented and not yet revenue-generating.
- Net sales were
$3.0 million , compared to$2.5 million in the first quarter of 2021, or a20% increase. Growth driven by a29% increase in recurring revenues. - Gross margin was
27% for the quarter, compared to36% in the first quarter of 2021. The decrease in gross margins resulted from continued increases in the costs of inputs to production and other factors. - Selling, general, and administrative (SG&A) costs for the quarter were
$10.7 million , compared to$14.0 million from the same quarter of the prior year. SG&A costs for the quarter excluding non-cash stock-based compensation were$8.2 million , compared to$8.0 million from the same quarter of the prior year. Cash used in SG&A was relatively unchanged. - Research and development (R&D) costs for the quarter were
$6.0 million , compared to$6.9 million from the same quarter of the prior year. R&D costs, excluding non-cash stock-based compensation expense, for the quarter were$5.7 million , compared to$4.1 million from the quarter of the prior year. Cash used in R&D increased due to Arc-related study spend and investment in Pheno II. - Net loss was
$14.2 million in the first quarter, resulting in$0.21 net loss per share. Net loss excluding non-cash stock-based compensation expense for the first quarter was$11.2 million . - Net cash used in the quarter was
$13.2 million , and the company ended the quarter with total cash, investments, and cash equivalents of$50.4 million . - Raised
$4.0 million from an insider financing round. - Reduced debt by
$14.0 million during the quarter through an equity exchange with principal bond holder. - Launched Accelerate Arc system and associated consumable kit for blood culture samples during the quarter.
Full financial results for the quarter ending March 31, 2022, will be filed on Form 10-Q through the Securities and Exchange Commission's (SEC) website at http://www.sec.gov.
Audio Webcast and Conference Call
To listen to the 2022 first quarter financial results, call by phone, +1.877.883.0383 and enter Elite Entry Number: 0355137. International participants may dial +1.412.902.6506. Please dial in 10–15 minutes prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 5137603 until June 6, 2022.
This conference call will also be webcast and can be accessed from the company's website at ir.axdx.com. A replay of the audio webcast will be available until August 15, 2022.
Use of Non-GAAP Financial Measures
This press release contains certain financial measures that are not recognized measures under accounting principles generally accepted in the United States of America ("GAAP"), which include SG&A, R&D, and Net income (loss) amounts excluding stock-based compensation expenses.
Our management and board of directors use expenses excluding the cost of stock-based compensation to understand and evaluate our operating performance and trends, to prepare and approve our annual budget and to develop short-term and long-term operating and financing plans. Accordingly, we believe that expenses excluding the cost of stock-based compensation provides useful information for investors in understanding and evaluating our operating results in the same manner as our management and our board of directors. Expenses excluding the cost of stock-based compensation is a non-GAAP financial measure and should be considered in addition to, not as superior to, or as a substitute for, SG&A expenses, R&D expenses, and net income (loss) reported in accordance with GAAP. The following tables present a reconciliation of SG&A expenses, R&D expenses and net income (loss) excluding stock-based compensation to comparable GAAP measures for the periods indicated:
Three Months Ended March 31, | ||
2022 | 2021 | |
Sales, general and administrative | ||
Non-cash equity-based compensation as a component of sales, general and administrative | 2,442 | 5,992 |
Sales, general and administrative less non-cash equity-based compensation | ||
Three Months Ended March 31, | ||
2022 | 2021 | |
Research and development | ||
Non-cash equity-based compensation as a component of research and development | 362 | 2,746 |
Research and development less non-cash equity-based compensation | ||
Three Months Ended March 31, | ||
2022 | ||
Net loss | ||
Non-cash equity-based compensation as a component of net loss | 2,979 | |
Net loss less non-cash equity-based compensation | ||
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate Arc™ system are designed to reduce the time clinicians must wait to determine the most optimal antibiotic therapy for bacteremic patients. These diagnostic systems are designed to serve clinical laboratories with automated solutions to expedite time to identification and antimicrobial susceptibility test (AST) results directly from positive blood culture samples. Multiple external studies have proven that Accelerate solutions deliver results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient's infection, days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and "ACCELERATE ARC" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward-looking or may have forward-looking implications. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 14, 2022, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
ACCELERATE DIAGNOSTICS, INC. | ||
March 31, | December 31, | |
2022 | 2021 | |
Unaudited | ||
ASSETS | ||
Current assets: | ||
Cash and cash equivalents | ||
Investments | 36,722 | 23,720 |
Trade accounts receivable | 2,114 | 2,320 |
Inventory | 5,505 | 5,067 |
Prepaid expenses | 1,522 | 768 |
Other current assets | 1,594 | 1,558 |
Total current assets | 61,111 | 73,331 |
Property and equipment, net | 5,108 | 5,389 |
Right of use assets | 2,347 | 2,510 |
Other non-current assets | 1,791 | 1,817 |
Total assets | ||
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
Current liabilities: | ||
Accounts payable | ||
Accrued liabilities | 4,086 | 2,853 |
Accrued interest | 156 | 909 |
Deferred revenue | 398 | 451 |
Current portion of long-term debt | 82 | 80 |
Current portion of finance lease | 76 | — |
Current operating lease liability | 699 | 669 |
Total current liabilities | 8,214 | 6,945 |
Finance lease, non-current | 164 | — |
Operating lease liability, non-current | 2,192 | 2,381 |
Other non-current liabilities | 805 | 808 |
Convertible notes | 115,758 | 107,984 |
Total liabilities | ||
Commitments and contingencies | ||
Stockholders' deficit: | ||
Preferred shares, | ||
5,000,000 preferred shares authorized and 3,954,546 outstanding as of March 31, 2022 and December 31, 2021 | 4 | 4 |
Common stock, | ||
100,000,000 common shares authorized with 68,711,633 shares issued and outstanding on March 31, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December 31, 2021 | 69 | 68 |
Contributed capital | 547,381 | 580,652 |
Treasury stock | (45,067) | (45,067) |
Accumulated deficit | (558,931) | (570,668) |
Accumulated other comprehensive loss | (232) | (60) |
Total stockholders' deficit | (56,776) | (35,071) |
Total liabilities and stockholders' deficit | ||
ACCELERATE DIAGNOSTICS, INC. | ||
Three Months Ended | ||
March 31, | March 31, | |
2022 | 2021 | |
Net sales | ||
Cost of sales | 2,156 | 1,621 |
Gross profit | 802 | 897 |
Costs and expenses: | ||
Research and development | 6,024 | 6,895 |
Sales, general and administrative | 10,673 | 14,029 |
Total costs and expenses | 16,697 | 20,924 |
Loss from operations | (15,895) | (20,027) |
Other income (expense): | ||
Interest expense | (917) | (4,090) |
Gain on extinguishment of debt | 2,646 | — |
Foreign currency exchange loss | 9 | (159) |
Interest income | 22 | 43 |
Other expense, net | (50) | (6) |
Total other income (expense), net | 1,710 | (4,212) |
Net loss before income taxes | (14,185) | (24,239) |
Provision for income taxes | — | — |
Net loss | ||
Basic and diluted net loss per share | ||
Weighted average shares outstanding | 67,755 | 58,520 |
Other comprehensive loss: | ||
Net loss | ||
Net unrealized loss on debt securities available-for-sale | (93) | (19) |
Foreign currency translation adjustment | (79) | (81) |
Comprehensive loss | ||
ACCELERATE DIAGNOSTICS, INC. | ||
Three Months Ended | ||
March 31, | March 31, | |
2022 | 2021 | |
Cash flows from operating activities: | ||
Net loss | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 616 | 659 |
Amortization of investment discount | 54 | 49 |
Equity-based compensation | 2,979 | 8,839 |
Amortization of debt discount and issuance costs | 163 | 2,996 |
Loss on disposal of property and equipment | 152 | — |
Gain on extinguishment of debt | (2,647) | — |
(Increase) decrease in assets: | ||
Contributions to deferred compensation plan | (5) | (112) |
Accounts receivable | 206 | (401) |
Inventory | (653) | (683) |
Prepaid expense and other | (714) | (292) |
Increase (decrease) in liabilities: | ||
Accounts payable | 1,154 | 575 |
Accrued liabilities | 1,081 | 183 |
Accrued interest | (751) | (1,048) |
Deferred revenue and income | (53) | (19) |
Deferred compensation | (3) | 118 |
Net cash used in operating activities | (12,606) | (13,375) |
Cash flows from investing activities: | ||
Purchases of equipment | (447) | — |
Purchase of marketable securities | (24,144) | (7,307) |
Maturities of marketable securities | 10,950 | 15,829 |
Net cash (used in) provided by investing activities | (13,641) | 8,522 |
Cash flows from financing activities: | ||
Proceeds from issuance of common stock | — | 10,666 |
Proceeds from exercise of options | — | 1,109 |
Proceeds from issuance of common stocks under employee purchase plan | 77 | 80 |
Net cash provided by financing activities | 77 | 11,855 |
Effect of exchange rate on cash | (74) | (57) |
(Decrease) increase in cash and cash equivalents | (26,244) | 6,945 |
Cash and cash equivalents, beginning of period | 39,898 | 35,781 |
Cash and cash equivalents, end of period | ||
ACCELERATE DIAGNOSTICS, INC. | ||
Three Months Ended | ||
March 31, | March 31, | |
2022 | 2021 | |
Non-cash investing activities: | ||
Net transfer of instruments from inventory to property and equipment | ||
Supplemental cash flow information: | ||
Interest paid | ||
Extinguishment of Convertible Senior Notes through issuance of common stock | $— | |
See accompanying notes to condensed consolidated financial statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-reports-first-quarter-2022-financial-results-301547440.html
SOURCE Accelerate Diagnostics, Inc.
FAQ
What were the financial results for AXDX in Q1 2022?
How many instruments were live in the U.S. for AXDX by the end of Q1 2022?
What was the gross margin for AXDX in Q1 2022?
Did AXDX raise any funds in Q1 2022?
What was the net loss for AXDX in Q1 2022?
